Valuation: Daré Bioscience, Inc.

Market Cap 11.86M 10.4M 9.83M 8.96M 16.76M 1.14B 16.88M 118M 45.55M 581M 44.52M 43.56M 1.87B P/E 2026 *
-1x
P/E 2027 * -1.87x
Enterprise Value 11.86M 10.4M 9.83M 8.96M 16.76M 1.14B 16.88M 118M 45.55M 581M 44.52M 43.56M 1.87B EV / Sales 2026 *
4.36x
EV / Sales 2027 * 1.34x
Free-Float
87.92%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Daré Bioscience, Inc.

1 day+4.73%
1 week-1.12%
Current month+1.91%
1 month-5.51%
3 months-61.22%
6 months-44.61%
Current year-59.82%
1 week 0.71
Extreme 0.7117
0.88
1 month 0.69
Extreme 0.69
0.88
Current year 0.69
Extreme 0.69
3.78
1 year 0.69
Extreme 0.69
3.78
3 years 0.69
Extreme 0.69
9.19
5 years 0.69
Extreme 0.69
30.12
10 years 0.69
Extreme 0.69
79.47
Manager TitleAgeSince
Chief Executive Officer 59 2017-06-30
Chief Tech/Sci/R&D Officer - 2021-12-31
Chief Tech/Sci/R&D Officer - 2021-12-31
Director TitleAgeSince
Director/Board Member 59 2017-06-30
Director/Board Member 71 2014-09-30
Chairman 78 2019-07-10
Date Insider Type Main position Quantity % Market Cap. Importance
6/30/26 Free

Director

30,805 0.2056%
6/30/26 Free

Director

26,540 0.1772%
6/30/26 Free

Director

23,696 0.1582%
Change 5-day change 1-year change 3-year change Capi.($)
+4.73%-1.12%-62.72%-86.28% 11.86M
+0.13%+2.65%+65.61%+114.28% 1,055B
+0.20%+0.46%+52.60%+69.24% 654B
-0.29%+0.14%+20.96%+70.93% 467B
-0.85%+0.98%+41.29%+44.38% 348B
+0.71%+4.08%+22.24%+29.51% 275B
+1.23%+0.42%+14.57%+12.13% 258B
+2.11%+7.51%+52.89%+55.37% 224B
+0.83%+0.55%+35.99%+101.70% 187B
0.00%-10.14%-29.94%-60.30% 171B
Average +0.80%+0.55%+21.35%+35.10% 363.84B
Weighted average by Cap. +0.02%+1.32%+41.53%+67.83%

Financials

2026 *2027 *
Net sales 2.72M 2.38M 2.25M 2.05M 3.84M 260M 3.87M 26.95M 10.44M 133M 10.2M 9.98M 428M 8.86M 7.78M 7.35M 6.69M 12.53M 850M 12.62M 87.9M 34.05M 434M 33.28M 32.56M 1.39B
Net income -12.99M -11.4M -10.76M -9.81M -18.36M -1.24B -18.49M -129M -49.89M -636M -48.76M -47.71M -2.04B -12.07M -10.59M -10M -9.12M -17.06M -1.16B -17.19M -120M -46.36M -591M -45.32M -44.34M -1.9B
Net Debt - -
Logo Daré Bioscience, Inc.
Dare Bioscience, Inc. is a biopharmaceutical company. The Company's programs target unmet needs in women's health, primarily in the areas of contraception, sexual health, pelvic pain, fertility, infectious disease, vaginal health and menopause. Its product includes XACIATO (clindamycin phosphate) vaginal gel 2%. XACIATO is a single-dose prescription medication for the treatment of bacterial vaginosis in females 12 years of age and older. Its other product candidates include Ovaprene, Sildenafil Cream, and DARE-HRT1. Ovaprene is an investigational, hormone-free, monthly intravaginal contraceptive. Sildenafil Cream is a novel cream formulation of sildenafil for the treatment of female sexual arousal disorder; and DARE-HRT1 is an intravaginal ring designed to deliver a combination of menopausal hormone therapy, bio-identical 17b-estradiol and progesterone together, continuously over a 28-day period for the treatment of moderate to severe vasomotor symptoms, also known as hot flashes.
Employees
23
Date Price Change Volume
26-09-25 US$0.7755 +4.73% 119,244
26-09-24 US$0.7405 -8.29% 469,509
26-09-23 US$0.8074 -5.01% 100,038
26-09-22 US$0.8500 +4.94% 245,720
26-09-21 US$0.8100 +3.28% 279,933
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
0.7755USD
Average target price
8.333USD
Spread / Average Target
+974.58%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. DARE Stock